Allemannsdata Wiki
Manual search

BIOVOTEC AS

Organization number 913037790 · Aksjeselskap

Programmatic access to company data (JSON)

Source: Firmafakta. Data read and page generated 2026-09-09T05:52:36Z. HTML cache: no-store (TTL 0 seconds). Default TTL for Firmafakta JSON/API responses: 60 seconds.

Facts

Source: Firmafakta, with business data from public registers.

organisasjonsnummer:
913037790
navn:
BIOVOTEC AS
organisasjonsform:
kode:
AS
beskrivelse:
Aksjeselskap
naeringskode1:
kode:
72.100
beskrivelse:
Forskning og eksperimentell utvikling innenfor naturvitenskap og teknikk
antallAnsatte:
not reported by source
hjemmeside:
www.biovotec.com
epostadresse:
not reported by source
telefon:
not reported by source
forretningsadresse:
adresse:
Haakon VIIs gate 5
poststed:
OSLO
postnummer:
0161
kommune:
OSLO
stiftelsesdato:
2014-01-01
registreringsdatoenhetsregisteret:
2014-01-07
aktivitet:
Utvikling av produkter og tjenester relatert til eggeskallmembran og, derivater derav, salg av produkter, utstyr og tjenester relatert til, dette, konsulenttjenester samt og investeringer i verdipapirer, relatert til dette området.
vedtektsfestetFormaal:
Utvikling av produkter og tjenester relatert til eggeskallmembran og, derivater derav, salg av produkter, utstyr og tjenester relatert til, dette, konsulenttjenester samt og investeringer i verdipapirer, relatert til dette området.

View the address in Geonorge

Board and other roles

Source: Firmafakta. Also see the separate Brønnøysund lookup under related lookups.

Regnskapsfører

Revisor

Styre

Owners

Source: Firmafakta shareholder dataset.

Showing top 50 of 151 shareholders by holding size. Raise 'limit' (max 1000) for more.

  1. JESUS SAA REQUEJO – 14.41 % (178034 shares, share class: NO0010789415)
  2. ALYLA AS – 12.09 % (149335 shares, share class: NO0010789415)
  3. BIOVOTEC AS – 9.14 % (112971 shares, share class: NO0010789415)
  4. TJELD AS – 6.93 % (85605 shares, share class: NO0010789415)
  5. FIRST PARTNERS HOLDING 8 AS – 5.98 % (73880 shares, share class: NO0010789415)
  6. BENARES AS – 5.82 % (71887 shares, share class: NO0010789415)
  7. HURD AS – 5.67 % (70000 shares, share class: NO0010789415)
  8. MIRAX AS – 4.46 % (55049 shares, share class: NO0010789415)
  9. HENRY SPERLE – 2.81 % (34667 shares, share class: NO0010789415)
  10. SKALTOR AS – 2.46 % (30380 shares, share class: NO0010789415)
  11. SARAFINA AS – 1.77 % (21852 shares, share class: NO0010789415)
  12. MAHA NORGE AS – 1.64 % (20224 shares, share class: NO0010789415)
  13. VALTOR AS – 1.3 % (16087 shares, share class: NO0010789415)
  14. STOKNES FUTURES AS – 1.28 % (15868 shares, share class: NO0010789415)
  15. VATLESTRAUMEN INVEST AS – 1.22 % (15033 shares, share class: NO0010789415)
  16. BARRY JOHN RICHARD O'CONNELL – 1.2 % (14809 shares, share class: NO0010789415)
  17. MATS MURI – 1.19 % (14701 shares, share class: NO0010789415)
  18. GLENNE INVEST AS – 1.07 % (13168 shares, share class: NO0010789415)
  19. AKROBAT INVEST AS – 0.99 % (12200 shares, share class: NO0010789415)
  20. CHRISTIAN SIBBERN – 0.96 % (11804 shares, share class: NO0010789415)
  21. KARIN FAREMO – 0.93 % (11458 shares, share class: NO0010789415)
  22. DMS INVEST AS – 0.92 % (11365 shares, share class: NO0010789415)
  23. LANGEFINNE AS – 0.89 % (10944 shares, share class: NO0010789415)
  24. KJELL HERMANN SKREDE – 0.85 % (10454 shares, share class: NO0010789415)
  25. UTGARD AS – 0.84 % (10392 shares, share class: NO0010789415)
  26. THEMAR EIENDOM AS – 0.56 % (6888 shares, share class: NO0010789415)
  27. ROAR LØVVIKEN – 0.5 % (6147 shares, share class: NO0010789415)
  28. HUITFELDT-KAAS AS – 0.46 % (5715 shares, share class: NO0010789415)
  29. MUTLE AS – 0.45 % (5609 shares, share class: NO0010789415)
  30. FINN INGARD JOHANSSON – 0.43 % (5329 shares, share class: NO0010789415)
  31. ODD HAMMERNES – 0.41 % (5098 shares, share class: NO0010789415)
  32. ØYVIND SOMMER ANDREASSEN – 0.37 % (4619 shares, share class: NO0010789415)
  33. HARALD MAGNUS SOMMER ANDREASSEN – 0.36 % (4458 shares, share class: NO0010789415)
  34. NICHOLAS GAY BERRYMAN – 0.36 % (4430 shares, share class: NO0010789415)
  35. REIDAR HAUG – 0.34 % (4171 shares, share class: NO0010789415)
  36. BRITT AMUNDSEN – 0.33 % (4103 shares, share class: NO0010789415)
  37. MONITA AS – 0.33 % (4034 shares, share class: NO0010789415)
  38. FIRIOL INVEST AS – 0.31 % (3814 shares, share class: NO0010789415)
  39. X MANU BHASKARAN – 0.31 % (3790 shares, share class: NO0010789415)
  40. SISSEL HANNISDAHL LOSSIUS – 0.29 % (3619 shares, share class: NO0010789415)
  41. PER ANDERS ELIND – 0.27 % (3354 shares, share class: NO0010789415)
  42. OVE LERDAHL AS – 0.27 % (3324 shares, share class: NO0010789415)
  43. SKREDE INVEST AS – 0.27 % (3300 shares, share class: NO0010789415)
  44. LYNG EIENDOM HOLDING AS – 0.26 % (3185 shares, share class: NO0010789415)
  45. JOHAN FREDRIK MOHN LIAN – 0.24 % (2959 shares, share class: NO0010789415)
  46. MIKKEL HANNISDAHL HAUG – 0.23 % (2899 shares, share class: NO0010789415)
  47. EIVIND MATS DUGSTAD – 0.23 % (2814 shares, share class: NO0010789415)
  48. ØYSTEIN HELLAND – 0.23 % (2788 shares, share class: NO0010789415)
  49. SMÅSTØLANE AS – 0.22 % (2711 shares, share class: NO0010789415)
  50. IVAR ANDREAS STROMPDAL – 0.19 % (2329 shares, share class: NO0010789415)

Fetch a longer owner list

Company holdings

Grants and support

Sources provided through Firmafakta: Innovation Norway, the EU, the Research Council of Norway and SkatteFUNN.

Innovasjon Norge (0)

No registered grants.

EU-tildelinger (3)

3 results

  1. id:
    1547
    rammeprogram:
    H2020
    prosjektnr:
    869943
    prosjektkortnavn:
    DERMAREP
    prosjektnavn:
    Clinical validation and production upscaling of a novel product for healing of Pressure Ulcers, Leg Ulcers and Diabetic Foot Ulcers.
    organisasjonsnummer:
    913037790
    organisasjonsnavn:
    BIOVOTEC AS
    kontrakt_startdato:
    01.10.2019 00:00
    kontrakt_sluttdato:
    30.09.2022 00:00
    innvilget_belop:
    885999.99999996
    program:
    not reported by source
    programomrade:
    Cross-theme
  2. id:
    2926
    rammeprogram:
    H2020
    prosjektnr:
    663509
    prosjektkortnavn:
    BIOCURE
    prosjektnavn:
    Novel Biomaterial for Improved and Cost-efficient Wound Healing
    organisasjonsnummer:
    913037790
    organisasjonsnavn:
    BIOVOTEC AS
    kontrakt_startdato:
    01.03.2015 00:00
    kontrakt_sluttdato:
    31.08.2015 00:00
    innvilget_belop:
    49999.99999998
    program:
    LEIT
    programomrade:
    Industrial Leadership
  3. id:
    1444
    rammeprogram:
    H2020
    prosjektnr:
    712445
    prosjektkortnavn:
    BIOCURE
    prosjektnavn:
    Novel Biomaterial for Improved and Cost-efficient Wound Healing
    organisasjonsnummer:
    913037790
    organisasjonsnavn:
    BIOVOTEC AS
    kontrakt_startdato:
    01.02.2016 00:00
    kontrakt_sluttdato:
    31.07.2018 00:00
    innvilget_belop:
    1181977.2999999
    program:
    LEIT
    programomrade:
    Industrial Leadership

Forskningsrådet (8)

8 results

  1. id:
    54136
    prosjektnummer:
    298764
    prosjekttittel:
    E!12852 A novel bio-material is to dramatically decrease the cost of treatment of severe wounds and burns.
    prosjektstart:
    2019
    prosjektslutt:
    2021
    prosjektansvarlig_navn:
    BIOVOTEC AS
    organisasjonsnummer:
    913037790
    sokt_belop:
    Dermatologi og venereologi
    tildelt_belop:
    0.0
    virkemiddel:
    Frittstående prosjekter
    aktivitet:
    Internasjonal prosjektstøtte
  2. id:
    51858
    prosjektnummer:
    290465
    prosjekttittel:
    A novel biomaterial is available to decrease cost of treatment of severe wounds.
    prosjektstart:
    2018
    prosjektslutt:
    2018
    prosjektansvarlig_navn:
    BIOVOTEC AS
    organisasjonsnummer:
    913037790
    sokt_belop:
    Basale med., odont. og veterinærmed. fag
    tildelt_belop:
    0.0
    virkemiddel:
    Nettverkstiltak
    aktivitet:
    Internasjonale nettverkstiltak
  3. id:
    51859
    prosjektnummer:
    290466
    prosjekttittel:
    Clinical validation and production upscaling of a novel product for healing of pressure and diabetic ulcers.
    prosjektstart:
    2018
    prosjektslutt:
    2019
    prosjektansvarlig_navn:
    BIOVOTEC AS
    organisasjonsnummer:
    913037790
    sokt_belop:
    Andre klinisk medisinske fag
    tildelt_belop:
    0.0
    virkemiddel:
    Nettverkstiltak
    aktivitet:
    Internasjonale nettverkstiltak
  4. id:
    37068
    prosjektnummer:
    256760
    prosjekttittel:
    First clinical studies on chronic wounds using a novel biomaterial - eggshell membrane
    prosjektstart:
    2016
    prosjektslutt:
    2018
    prosjektansvarlig_navn:
    BIOVOTEC AS
    organisasjonsnummer:
    913037790
    sokt_belop:
    Tverr/flerfaglig teknologi og andre fagområder
    tildelt_belop:
    0.0
    virkemiddel:
    Programmer
    aktivitet:
    Brukerstyrte innovasjonsprogrammer
  5. id:
    35445
    prosjektnummer:
    254623
    prosjekttittel:
    A new biomaterial available for wound healing (Project establishment support -PES2020 Eurostars)
    prosjektstart:
    2015
    prosjektslutt:
    2016
    prosjektansvarlig_navn:
    BIOVOTEC AS
    organisasjonsnummer:
    913037790
    sokt_belop:
    Tverr/flerfaglig innen teknologi
    tildelt_belop:
    0.0
    virkemiddel:
    Nettverkstiltak
    aktivitet:
    Internasjonale nettverkstiltak
  6. id:
    5436
    prosjektnummer:
    235545
    prosjekttittel:
    New skin regeneration and wound healing products from eggshell membrane
    prosjektstart:
    2014
    prosjektslutt:
    2017
    prosjektansvarlig_navn:
    BIOVOTEC AS
    organisasjonsnummer:
    913037790
    sokt_belop:
    Tverr/flerfaglig teknologi og andre fagområder
    tildelt_belop:
    0.0
    virkemiddel:
    Programmer
    aktivitet:
    Brukerstyrte innovasjonsprogrammer
  7. id:
    30288
    prosjektnummer:
    241290
    prosjekttittel:
    A new biomaterial available for wound healing
    prosjektstart:
    2014
    prosjektslutt:
    2014
    prosjektansvarlig_navn:
    BIOVOTEC AS
    organisasjonsnummer:
    913037790
    sokt_belop:
    Tverr/flerfaglig innen teknologi
    tildelt_belop:
    0.0
    virkemiddel:
    Nettverkstiltak
    aktivitet:
    Internasjonale nettverkstiltak
  8. id:
    30417
    prosjektnummer:
    241848
    prosjekttittel:
    Effects of eggshell membrane nano particles on calcium uptake to prevent osteoporosis
    prosjektstart:
    2014
    prosjektslutt:
    2015
    prosjektansvarlig_navn:
    BIOVOTEC AS
    organisasjonsnummer:
    913037790
    sokt_belop:
    Nanoteknologi
    tildelt_belop:
    0.0
    virkemiddel:
    Programmer
    aktivitet:
    Store programmer

SkatteFUNN (6)

6 results

  1. id:
    36190
    innsendt_dato:
    2015-08-20
    prosjektnummer:
    252437
    bedriftsnavn:
    BIOVOTEC AS
    prosjekttittel:
    New skin regeneration and wound healing products from eggshell membrane.
    organisasjonsnummer:
    913037790
    fylke:
    Oslo
    kommunenavn:
    Oslo
    poststed:
    OSLO
    soknad_godkjent:
    JA
    soknad_avslatt:
    NEI
    vedtaksdato:
    2015-08-28
    prosjekt_fra_ar:
    2015
    prosjekt_til_ar:
    2017
    sammendrag:
    not reported by source
  2. id:
    40063
    innsendt_dato:
    2016-08-05
    prosjektnummer:
    264172
    bedriftsnavn:
    BIOVOTEC AS
    prosjekttittel:
    Novel Biomaterial for Improved and Cost-efficient Wound Healing.
    organisasjonsnummer:
    913037790
    fylke:
    Oslo
    kommunenavn:
    Oslo
    poststed:
    OSLO
    soknad_godkjent:
    JA
    soknad_avslatt:
    NEI
    vedtaksdato:
    2016-08-18
    prosjekt_fra_ar:
    2016
    prosjekt_til_ar:
    2018
    sammendrag:
    not reported by source
  3. id:
    53433
    innsendt_dato:
    2019-06-03
    prosjektnummer:
    304120
    bedriftsnavn:
    BIOVOTEC AS
    prosjekttittel:
    A novel bio-material is to dramatically decrease the cost of treatment of severe wounds and burns.
    organisasjonsnummer:
    913037790
    fylke:
    Oslo
    kommunenavn:
    Oslo
    poststed:
    OSLO
    soknad_godkjent:
    JA
    soknad_avslatt:
    NEI
    vedtaksdato:
    2019-06-05
    prosjekt_fra_ar:
    2019
    prosjekt_til_ar:
    2021
    sammendrag:
    This project is the development of a novel 3D material derived from Purified Eggshell Protein (PEP), a readily available by-product from the egg industry: Egg Shell Membrane (ESM). Biovotec has already developed a dissolvable PEP-based 2D product, DermaRep, during successful SME 1 & 2 projects. Pre-clinical studies have shown that DermaRep is equivalent to collagen in the pig wound healing model. Now, it is entering clinical trials and expected to receive CE mark in 2020. However, its application only adequate for superficial wounds which have limited severity and depth. This project, DEEPCURE will be developed only for deep and severe wounds and burns and thus will be a logical, non-overlapping extension of the DermaRep line. The endpoint of this project is confirmation of biocompatibility and safety of the developed product in animal studies within 2 years from the start of the project. At the end of the project, the new 3D product will be ready for its final pre-clinical efficiency test. Our PEP based product line, DermaRep and upcoming DEEPCURE, is disruptive and we will become the benchmark in the wound healing market offering prices 5x lower than the competition, a major cost and time saving for hospitals.
  4. id:
    57404
    innsendt_dato:
    2020-03-04
    prosjektnummer:
    312165
    bedriftsnavn:
    BIOVOTEC AS
    prosjekttittel:
    Establishing data for CE marking followed by clinical efficiency trail and production optimization.
    organisasjonsnummer:
    913037790
    fylke:
    Oslo
    kommunenavn:
    Oslo
    poststed:
    OSLO
    soknad_godkjent:
    JA
    soknad_avslatt:
    NEI
    vedtaksdato:
    2020-04-03
    prosjekt_fra_ar:
    2020
    prosjekt_til_ar:
    2023
    sammendrag:
    The use of often poorly effective wound dressings due to the cost considerations and the resulting often prolonged healing time constitute a large burden on health service providers in addition to patient pain, morbidity and dependency. Our key clinical input was to develop a wound care dressing as effective as existing collagen product for enhancement of wound healing BUT at a significantly lower price. This was achieved by substituting collagen with an inexpensive biomaterial from a nonbovine animal source. Our unique and novel product DermaRep
  5. id:
    48425
    innsendt_dato:
    2018-02-21
    prosjektnummer:
    285633
    bedriftsnavn:
    BIOVOTEC AS
    prosjekttittel:
    Novel Biomaterial for Improved and Cost-efficient Wound Healing, first clinical studies.
    organisasjonsnummer:
    913037790
    fylke:
    Oslo
    kommunenavn:
    Oslo
    poststed:
    OSLO
    soknad_godkjent:
    JA
    soknad_avslatt:
    NEI
    vedtaksdato:
    2018-02-26
    prosjekt_fra_ar:
    2018
    prosjekt_til_ar:
    2019
    sammendrag:
    In this project Biovotec aims at clinically testing a novel cost-effective wound dressing based on a novel biomaterial derived from eggshell membrane to be used as first-line treatment in all wounds at risk of delayed or non-healing, reducing the incidence of chronic wounds, such as venous and diabetic ulcers. In order to do so, we have then set up the first of its kind manufacturing process steps done under the medical device ISO regulation. Our first medical device is a dissolvable film which addresses both the technical side but also on the cost side. We have through this established a pilot manufacturing process for the wound healing film device and successfully completed all preclinical tests required. We will now test the device clinically in both the UK and France.
  6. id:
    68306
    innsendt_dato:
    2023-08-28
    prosjektnummer:
    348002
    bedriftsnavn:
    BIOVOTEC AS
    prosjekttittel:
    DermaRep - product development, preclinical evaluation and process development and optimization.
    organisasjonsnummer:
    913037790
    fylke:
    Oslo
    kommunenavn:
    Oslo
    poststed:
    OSLO
    soknad_godkjent:
    JA
    soknad_avslatt:
    NEI
    vedtaksdato:
    2023-11-16
    prosjekt_fra_ar:
    2023
    prosjekt_til_ar:
    2025
    sammendrag:
    The use of often poorly effective wound dressings due to the cost considerations and the resulting often prolonged healing time constitute a large burden on health service providers in addition to patient pain, morbidity and dependency. Our key clinical input was to develop a wound care dressing as effective as existing collagen product for enhancement of wound healing BUT at a significantly lower price. This was achieved by substituting collagen with an inexpensive biomaterial from a nonbovine animal source. Our unique and novel product has successfully completed its first clinical trial and is now applying for FDA approval. The goal of this follow-on project is to R&D tests, optimize and scale up manufacture to reduce costs and show treatment cost effectiveness in a large statistically based clinical trial.

Subunits

Open positions

count:
0
stillinger:

No results.

Related lookups

How an AI agent should use this page

Ground rule: Navigate with HTML GET links to keep explanations and relationships. Use the page's JSON alternative only when concrete values must be extracted, compared or computed.

How to use the company page

  1. Use the organization number as the stable key.
  2. Distinguish between the company's own facts, roles, owners, holdings and grants.
  3. Follow person and company links to explore the graph; do not assume relations that are not explicitly registered.

Related services

Time: Ownership, roles and status can change. State the source and retrieval time with factual claims.

AI agent? Read the complete navigation and programming guide.